“At its core, our goal is to reduce uncertainty, improve outcomes, and make a tangible difference to patients and their families.” - Rick Morello, CEO, CND Life Sciences

Building a life sciences company is rarely linear. It sits at the intersection of scientific discovery, clinical need, and operational scale, requiring leadership that can translate complexity into real-world impact.

For the CEO of CND Life Sciences, Rick Morello, the past six years have been defined by transforming a scientific innovation into a national diagnostic platform supporting patients, clinicians, and the future of neurodegenerative disease treatment.

A mission-driven journey

“CND was built to advance human health in areas where patients and families face significant uncertainty.”

At its core, the journey has been driven by mission. Built alongside neurologist founders, CND has evolved from early-stage innovation into a national enterprise, with a clear focus on improving outcomes in some of the most complex areas of medicine.

Operating in neurodiagnostics brings inherent challenges. Conditions such as Parkinson’s disease and dementia with Lewy bodies are difficult to diagnose, often relying on interpretation rather than definitive testing. The Syn-One Test was developed to address this - offering a more precise and accessible diagnostic tool.

From innovation to everyday clinical practice

“Ensuring complex science can be adopted in everyday clinical practice has been just as critical as the innovation itself.”

Ensuring that innovation can be understood and adopted in practice has been central to CND’s approach, supported by close collaboration across medical, clinical, and commercial teams.

The impact is already evident. Nearly 50,000 patients have been supported through Syn-One in clinical practice, helping to increase diagnostic certainty where delays and misdiagnosis are common. Studies from institutions including Yale and the Cleveland Clinic have reinforced its clinical value, while involvement in pharmaceutical trials positions CND within a broader ecosystem advancing disease-modifying therapies.

“Greater diagnostic precision has a direct impact on patient outcomes.”

Building the team to scale

As the company has grown, so has the importance of building the right team. Scaling a diagnostics business requires not just expansion, but the ability to execute complex work with consistency and precision. Transformational hires - those who can integrate quickly, build trust, and deliver measurable impact - have been critical in supporting this next phase of growth.

Recent milestones reflect both progress and future potential. From serving 50,000 patients to achieving FDA Breakthrough Device Designation, and generating early data in detection and clinical trial settings, these developments point toward a shift in how neurodegenerative diseases may be diagnosed and managed.

“The opportunity lies in enabling earlier intervention that could meaningfully alter disease progression.”

Growth, however, brings its own challenges. Balancing increasing demand with the wellbeing of a highly committed workforce remains a constant focus, alongside the need to stay ahead of hiring and support long-term development.

Ultimately, success for CND Life Sciences is defined by its ability to change how these diseases are diagnosed and treated - giving patients the opportunity to maintain quality of life for longer.

“Reducing uncertainty and improving outcomes for patients.”